Month: September 2020

Rekstrarniðurstaða Hafnarfjarðarkaupstaðar fyirr A og B hluta fyrri hluta ársins 2020 var neikvæð um  459 milljónir króna en áætlun gerði ráð fyrir að rekstrarafgangur yrði 248 milljónir króna. Helstu frávik má rekja til tekjufalls vegna Covid-19. Útsvarstekjur voru um 478 milljónum króna undir áætlun, framlög jöfnunarsjóðs voru um 126 milljónun króna undir áætlun og aðrar tekjur voru einnig um 155 milljónum króna undir áætlun. Rekstrarkostnaður var hins vegar um 219 milljónum króna lægri en áætlun gerði ráð fyrir.Tekjur námu 14.067 milljónum króna sem er 760 milljónir undir áætlun. Laun og launatengd gjöld eru stærstu útgjaldaliðir sveitarfélagsins og námu þeir 7.114 milljónum króna sem er í takt við áætlun. Annar kostnaður var 5.317 milljónir króna sem er um 216 milljónum króna undir áætlun.Rekstur málaflokka gekk vel og var í takt...

Nasdaq Stockholms disciplinnämnd ålägger WESTPAY AB vite motsvarande 2 årsavgifter för informationsgivningsmisstag.Westpay AB (”Bolaget”) har underrättats om beslut från disciplinnämnden vid Nasdaq Stockholm om att Bolaget åläggs att betala ett vite motsvarande två årsavgifter a’ SEK 100 000 för att vid ett tillfälle ej ha offentliggjort information i enlighet med regelverket för Nasdaq First North Growth Market.För mer info: https://newsclient.omxgroup.com/cdsPublic/viewDisclosure.action?disclosureId=954800&lang=en For additional information, please contact:Sten Karlsson, CEO Westpay ABMobile: +46 70-555 6065Email: sten.karlsson@westpay.seHans Edin, CCO Westpay ABMobile: +46 70-688 02 05Email: hans.edin@westpay.seWestpay’s Certified Adviser is Erik Penser Bank,phone: +46 8-463 80 00, email: certifiedadviser@penser.seAttachmentPressrelease_20200910_Decision_Disciplinary...

Worldline’s tender offer for Ingenico:Precisions on the timetable for the European Commission’s review of the transactionBezons and Paris, September 10th, 2020Following the publication by the European Commission of the deadline for the completion of its review of the transaction, now set for September 30th, 2020, Worldline expects that, subject to the approval of the transaction by the European Commission, Worldline’s tender offer for Ingenico’s securities should close around October 15th, 2020 in line with the indicative timetable.In this context, the process with the European Commission is progressing normally, in line with what was initially planned, notably in terms of deadlines. The remedies envisaged for a limited number of countries, given the high complementarity of the two groups, are limited and consistent...

Offre publique de Worldline sur Ingenico : précisions sur le calendrier d’examen de l’opération par la Commission européenneBezons et Paris, le 10 septembre 2020A la suite de la publication par la Commission européenne de la date limite de son examen de l’opération à présent fixée au 30 septembre 2020, Worldline estime que, sous réserve d’autorisation de l’opération par la Commission européenne, l’offre publique de Worldline visant les titres Ingenico devrait clôturer aux alentours du 15 octobre 2020 en ligne avec le calendrier indicatif.Dans ce cadre, le processus avec la Commission européenne suit normalement son cours, en ligne avec ce qui était initialement prévu notamment en termes de délais. Les remèdes envisagés pour un nombre réduit de pays, du fait de la très grande complémentarité des deux groupes, sont limités et cohérents...

     AMENDMENT – FORM 8.5 (EPT/RI)PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY1.         KEY INFORMATION2.         DEALINGS BY THE EXEMPT PRINCIPAL TRADER(a)        Purchases and sales(b)        Derivatives transactions (other than options)(c)        Options transactions in respect of existing securities(i)         Writing, selling, purchasing or varying(ii)        Exercising(d)        Other dealings (including subscribing for new securities)The currency of all prices and other monetary amounts should be stated.Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.3.         OTHER...

VANCOUVER, British Columbia, Sept. 10, 2020 (GLOBE NEWSWIRE) — P2 Gold Inc. (“P2” or the “Company”) (TSX-V:PGLD) reports that, subject to regulatory approval, it has signed a mineral lease and option agreement with La Cuesta International, Inc. (“La Cuesta”), an arm’s length private company, to lease a 100% interest in the Lost Cabin Property located in south central Oregon.Lost CabinThe Lost Cabin Property consists of 106 unpatented lode mining claims that cover an area of over 2,190 acres, located in Lake County, Oregon.  The property is located along a major-northwest-trending structural lineament and hydrothermal alteration associated with silicic volcanism.The principals of La Cuesta are Perry Durning and Frank (Bud) Hillemeyer, who received the PDAC Thayer Lindsley International Mineral Discoveries Award in 2010.La Cuesta...

09:30 London, 11:30 Helsinki, 10 September 2020 – Afarak Group Plc (“Afarak” or “the Company”) (LSE: AFRK, NASDAQ: AFAGR)AFARAK MOGALE (PTY) LTD (IN BUSINESS RESCUE) – PROPOSED BUSINESS RESCUE PLANStock Exchange ReleaseThe business rescue practitioners in Afarak Mogale (Pty) Ltd (”Mogale”) circulated to all stakeholders a proposed business rescue plan prepared in terms of Section 150 of the Companies Act, and that a meeting will be held on 16 September 2020.If the proposed business rescue plan is accepted, it will lead to a loss of control and reclassification to discontinued operation of Mogale. The impact is currently being assessed and will be quantified after approval of the plan, though we do not expect that this loss of control will have a negative accounting impact.Helsinki, September 10, 2020AFARAK...

09:30 Lontoo, 11:30 Helsinki, 10.9.2020 – Afarak Group Oyj (”Afarak” tai ”Yhtiö) (LSE: AFRK, NASDAQ: AFAGR)AFARAK MOGALE (PTY) LTD (BUSINESS RESCUE -SANEERAUSMENETTELYSSÄ) – SANEERAUSOHJELMAEHDOTUSPörssitiedoteAfarak Mogale (Pty) Ltd:n (”Mogale”) Business Rescue -saneerausmenettelyn selvittäjät toimittivat Etelä-Afrikan Companies Act -yhtiölain kohdan 150 mukaisesti laaditun saneerausohjelmaehdotuksen sidosryhmille, ja kokous tullaan pitämään 16.9.2020.Jos saneerausohjelmaehdotus hyväksytään, johtaa tämä määräysvallan menettämiseen ja Mogalen uudelleenluokittelemiseen lopetetuksi toiminnoksi. Vaikka yhtiö arvioi, ettei määräysvallan menettämisellä ole negatiivisia kirjanpidollisia vaikutuksia, näitä arvioidaan parhaillaan ja ne tullaan määrittämään ehdotuksen hyväksymisen jälkeen.Helsingissä, 10.9.2020AFARAK GROUP OYJHallitusLisätietoja:Afarak...

Opaganib remt de virale replicatie van SARS-CoV-2 volledig, zoals gemeten na drie dagen incubatie in een in-vitro model van humaan bronchiaal weefsel; en kent een gunstige vergelijking met remdesivir, de positieve controle in het onderzoek—Opaganib heeft een unieke positie als een oraal toegediende mogelijke behandeling voor COVID-19, waarbij krachtige antivirale en ontstekingsremmende werkingsmechanismen worden gecombineerd, gericht op een component van de gastheercel en het minimaliseren van de kans op weerstand—Lopende, wereldwijde fase 2/3 en Amerikaanse fase 2 klinische studies met opaganib voor ernstige longontsteking veroorzaakt door COVID-19 —Het tweede kandidaat-geneesmiddel van RedHill voor COVID-19, RHB-107 (upamostat), een nieuwe serine-proteaseremmer, remt de virale replicatie van SARS-CoV-2 sterk in hetzelfde...

L’opaganib inhibe complètement la réplication virale du SARS-CoV-2 telle que mesurée après trois jours d’incubation dans un modèle in vitro de tissu bronchique humain, ce qui le compare favorablement au remdesivir, le contrôle positif dans l’étude—L’opaganib occupe une position unique en tant que traitement potentiel de la COVID-19 administré par voie orale en combinant des mécanismes d’action puissants, anti-viraux et anti-inflammatoires, et en ciblant un composant cellulaire hôte et en minimisant la probabilité de résistance—Études cliniques de phase 2 et 3 dans le monde, et de phase 2 aux États-Unis en cours avec l’opaganib pour la pneumonie sévère due à la COVID-19  —Le deuxième médicament candidat contre la COVID-19 de RedHill, le RHB-107 (upamostat), un nouvel inhibiteur de protéase...